Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class ...
The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.
Under a research collaboration first established in 2021, Astellas Pharma is moving to license a Dyno Therapeutics gene therapy vehicle—an adeno-associated virus (AAV) capsid engineered for ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Astellas Pharma Inc. (TSE: ...
AI-assisted adeno-associated virus (AAV) capsid engineering has transformative potential in terms of accelerating and optimizing the development of gene therapies. That’s the view of Fangzhi Tan, PhD, ...
Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to ...
A collaborative research team led by Kazuyoshi Murata determined the capsid structure of the giant Melbournevirus at 4.4 Å resolution using cryo-electron microscopy. By applying a block-based ...
From a virus's point of view, invading our cells is a matter of survival. The virus makes a living by highjacking cellular processes to produce more of the proteins that make it up. From our point of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results